Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy

A Modeling Study

Published in: Cancer Epidemiology Biomarkers & Prevention [Epub November 2017]. doi: 10.1158/1055-9965.EPI-17-0378

Posted on RAND.org on January 24, 2018

by Carolyn M. Rutter, Jane J. Kim, Reinier G. Meester, Brian L. Sprague, Emily Burger, Ann G. Zauber, Mehmet Ali Ergun, Nicole G. Campos, Chyke A. Doubeni, Amy Trentham-Dietz, Stephen Sy, Oguzhan Alagoz, Natasha K. Stout, Iris Lansdorp-Vogelaar, Douglas A. Corley, Anna N. Tosteson

Read More

Access further information on this document at American Association for Cancer Research

This article was published outside of RAND. The full text of the article can be found at the link above.

Background

Patients who receive an abnormal cancer screening result require follow-up for diagnostic testing, but the time to follow-up varies across patients and practices.

Methods

We used a simulation study to estimate the change in lifetime screening benefits when time to follow-up for breast, cervical, and colorectal cancers was increased. Estimates were based on four independently developed microsimulation models that each simulated the life course of adults eligible for breast (women aged 50–74 years), cervical (women aged 21-65 years), or colorectal (adults aged 50–75 years) cancer screening. We assumed screening based on biennial mammography for breast cancer, triennial Papanicolaou testing for cervical cancer, and annual fecal immunochemical testing for colorectal cancer. For each cancer type, we simulated diagnostic testing immediately and at 3, 6 and 12 months after an abnormal screening exam.

Results

We found declines in screening benefit with longer times to diagnostic testing, particularly for breast cancer screening. Compared to immediate diagnostic testing, testing at 3 months resulted in reduced screening benefit, with fewer undiscounted life years gained per 1000 screened (breast: 17.3%, cervical: 0.8%, colorectal: 2.0% and 2.7% (from two colorectal cancer models), fewer cancers prevented (cervical: 1.4% fewer, colorectal: 0.5% and 1.7% fewer, respectively) and, for breast and colorectal cancer, a less favorable stage distribution.

Conclusions

Longer times to diagnostic testing after an abnormal screening test can decrease screening effectiveness, but the impact varies substantially by cancer type. Impact: Understanding the impact of time to diagnostic testing on screening effectiveness can help inform quality improvement efforts.

This report is part of the RAND Corporation external publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.